Johnson & Johnson’s MedTech division announced in July 2026 that it had received its first U.S. regulatory authorization for Ottava, the company’s long-delayed soft-tissue surgical robot, giving the world’s largest medical device maker a foothold in a robotic surgery market it has chased for more than ten years.
A Decade in the Making
J&J first signaled its ambitions in robotic surgery back in 2015 through its Verb Surgical joint venture with Alphabet’s Verily, later folded fully into J&J and rebranded as Ottava. The program went through repeated redesigns, regulatory setbacks and delayed timelines that stretched a project originally expected to reach the market by the late 2010s into a decade-long build. The July 2026 clearance marks the first time any version of the platform has received U.S. authorization for use in soft-tissue procedures.
Why Soft Tissue Is the Battleground
Soft-tissue robotic surgery — procedures on organs like the bladder, prostate, colon and gynecologic tissue — is the segment Intuitive Surgical has dominated for two decades with its da Vinci systems, which are used in well over a million procedures a year worldwide. Ottava is designed to compete directly in that space, and J&J has emphasized integrated imaging and instrument-tracking software that layers AI-assisted guidance on top of the mechanical platform, aiming to give surgeons real-time visual cues during a procedure rather than just steadier hands than a human alone.
Not the Only New Entrant
Ottava arrives alongside a wave of new competitors chasing Intuitive’s lead. CMR Surgical’s Versius Plus is on track for a U.S. launch in 2026, Medtronic’s Hugo system won FDA clearance for urologic procedures in December 2025, and Revolve Surgical secured 510(k) clearance for a first-in-class, zero-footprint robotic platform earlier this year. Industry analysts tracking the space describe 2026 as the most competitive year yet in soft-tissue robotic surgery, with multiple well-capitalized entrants finally reaching the market at roughly the same time after years of parallel development.
What Hospitals Are Watching
For hospital purchasing committees, the calculus goes beyond which robot has the steadiest arm. Multi-year service contracts, per-procedure instrument costs, surgeon retraining time and integration with existing operating-room imaging systems all factor into buying decisions that can run into the tens of millions of dollars for a single system. J&J’s scale — it already sells sutures, staplers, energy devices and other surgical tools to nearly every hospital in the country — gives it a distribution and relationship advantage that smaller robotics-only competitors lack, even if its robot arrives to market a decade later than planned.
The Case for Caution
Surgeons and hospital safety officers who have lived through prior robotic-surgery rollouts urge patience before assuming AI-guided robotics improve outcomes broadly. Early studies of first-generation surgical robots found mixed results on complication rates depending on procedure type and surgeon experience, and some hospital systems delayed wider adoption of earlier platforms until multi-year outcome data accumulated. With Ottava, Hugo, Versius Plus and Revolve all reaching the market in the same window, health systems will likely be running real-world comparisons for the first time at scale, and some clinicians argue regulators and hospitals should be tracking complication and revision-surgery rates across all four platforms rather than trusting each manufacturer’s own clinical trial data in isolation.
The Road Ahead
J&J has not disclosed exactly how many Ottava units it plans to place in U.S. hospitals in the initial rollout, but company executives have described 2026 and 2027 as the years the platform moves from limited early-access sites to broader commercial availability. With four major systems now cleared or nearly cleared in the same year, the next phase of the story will likely be less about who gets FDA approval first and more about whose robot — and whose AI-guided software layered on top of it — actually shows up in outcome data as making surgery measurably safer.
Photo: Zakir Rushanly / PEXELS via Pexels
